视网膜病变治疗市场规模、份额、成长分析（按类型、按药房、按分销管道、按地区）－2025 年至 2032 年产业预测

预计到 2023 年视网膜疾病治疗市场规模将达到 119.2 亿美元，从 2024 年的 130.5 亿美元成长到 2032 年的 268.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 9.45%。

由于人口老化和糖尿病发生率上升，老龄化黄斑部病变（AMD）和糖尿病视网膜病变等疾病的盛行率不断上升，全球视网膜疾病治疗市场正在快速发展。未治疗的视网膜疾病会造成视力障碍和失明的风险，因此对有效治疗的需求迅速增加。关键创新包括抗 VEGF 疗法，例如Lucentis和 Eylea，它们改变了湿性AMD和糖尿病视网膜病变的治疗。此外，基因和干细胞治疗的进步有望成为遗传疾病的长期解决方案。增强的视网膜成像技术有助于早期诊断和个人化治疗。但挑战依然存在，包括高昂的治疗成本和监管障碍。随着研发的进步，市场预计将持续成长，最终改善患者的治疗效果和生活品质。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

视网膜疾病治疗市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• 黄斑部病变
  • 干性黄斑部病变
  • 湿性黄斑部病变
• 糖尿病视网膜病变
• 其他的

视网膜疾病治疗市场规模（按配药类型和复合年增长率） (2025-2032)

• 市场概览
• 凝胶
• iSolutions
• 胶囊和锭剂
• 眼药水
• 软膏

视网膜疾病治疗市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 网路药局
• 零售药局

视网膜疾病治疗市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Regeneron Pharmaceuticals, Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• AbbVie Inc.（USA）
• Pfizer, Inc.（USA）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• Alcon Inc.（Switzerland）
• Bausch Health Companies Inc.（Canada）
• Merck & Co., Inc.（USA）
• Biogen Inc.（USA）
• Alimera Sciences, Inc.（USA）
• Graybug Vision, Inc.（USA）
• Kubota Pharmaceutical Holdings Co., Ltd.（Japan）
• Allergan plc（Ireland）（Now part of Abbvie）
• Ophthotech Corporation（USA）
• Genentech（USA）（Part of Roche）
• EyeBio（USA）（Acquired by Merck）
• Carl Zeiss Meditec AG（Germany）

结论和建议

Retinal Disorder Treatment Market size was valued at USD 11.92 billion in 2023 and is poised to grow from USD 13.05 billion in 2024 to USD 26.87 billion by 2032, growing at a CAGR of 9.45% during the forecast period (2025-2032).

The global retinal disorder treatment market is rapidly evolving, driven by the increasing prevalence of conditions like age-related macular degeneration (AMD) and diabetic retinopathy, largely due to aging populations and rising diabetes rates. With untreated retinal disorders posing risks of vision impairment and blindness, demand for effective treatments is surging. Key innovations include anti-VEGF therapies, such as Lucentis and Eylea, which have transformed wet AMD and diabetic retinopathy management. Additionally, advancements in gene and stem cell therapies offer promising long-term solutions for inherited disorders. Enhanced retinal imaging technologies are facilitating earlier diagnosis and personalized treatments. However, challenges such as high treatment costs and regulatory hurdles persist. As R&D efforts progress, the market is poised for continued growth, ultimately improving patient outcomes and quality of life.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disorder Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disorder Treatment Market Segments Analysis

Global Retinal Disorder Treatment Market is segmented by Type, Dosage, Distribution Channel and region. Based on Type, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Dosage, the market is segmented into Gels, Eye Solutions, Capsules & Tablets, Eye Drops and Ointments. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Disorder Treatment Market

The growing aging population serves as a major catalyst for the retinal disorder treatment market. As individuals age, their risk of developing a range of eye conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, significantly increases. With the global elderly demographic expanding, a corresponding rise in the incidence of retinal disorders is anticipated, which will consequently boost the demand for effective treatments and therapies for these conditions. This demographic trend underscores the urgency for advancements in the treatment of retinal disorders, thereby shaping the market dynamics and influencing healthcare strategies aimed at addressing these age-related eye issues.

Restraints in the Retinal Disorder Treatment Market

The retinal disorder treatment market faces notable constraints primarily due to the high costs associated with various treatment options. Many therapies, such as anti-VEGF solutions and surgical interventions, come with considerable expenses that may hinder patient access. This financial burden is particularly impactful in areas with limited healthcare resources or where insurance coverage is inadequate, ultimately restricting the availability of necessary treatments for patients in need. Consequently, these economic barriers can impede the overall growth and development of the retinal disorder treatment market, as a significant portion of the population may remain untreated or under-treated.

Market Trends of the Retinal Disorder Treatment Market

The Retinal Disorder Treatment market is witnessing a notable trend characterized by significant advancements in retinal imaging and diagnostic technologies. Innovations such as optical coherence tomography (OCT) and adaptive optics have revolutionized early detection of retinal disorders, allowing for timely interventions that mitigate potential vision loss. Furthermore, the incorporation of artificial intelligence (AI) and machine learning into imaging processes has increased diagnostic accuracy and efficiency, enabling healthcare providers to make more informed treatment decisions. This shift towards early diagnosis and AI-driven diagnostics not only enhances patient outcomes but also drives demand in the retinal treatment landscape, securing a robust growth trajectory for the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Retinal Disorder Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
  • Dry Macular Degeneration
  • Wet Macular Degeneration
• Diabetic Retinopathy
• Others

Global Retinal Disorder Treatment Market Size by Dosage & CAGR (2025-2032)

• Market Overview
• Gels
• Eye Solutions
• Capsules & Tablets
• Eye Drops
• Ointments

Global Retinal Disorder Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Retinal Disorder Treatment Market Size & CAGR (2025-2032)

• North America (Type, Dosage, Distribution Channel)
  • US
  • Canada
• Europe (Type, Dosage, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Dosage, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Dosage, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Dosage, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kubota Pharmaceutical Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)(Now part of Abbvie)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ophthotech Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech (USA)(Part of Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyeBio (USA)(Acquired by Merck)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations